NAD recommends Promensil claims changes
This article was originally published in The Tan Sheet
Executive Summary
Natrol's advertising for Promensil red clover dietary supplement for relief of menopause symptoms "overstates the results" of research used to back its claims and the firm should modify them accordingly, the National Advertising Division of the Council of Better Business Bureaus states Sept. 18. NAD reviewed claims including, "Why Promensil ... 22 clinical studies can't be wrong," and "Clinically Proven and Doctor Recommended." The group examined Natrol's research and found conflicting efficacy research and deficiencies in the study data provided by the Chatsworth, Calif.-based firm. However, Natrol provided a reasonable basis to make certain limited claims that Promensil can help relieve the frequency and/or severity of hot flashes, increase testosterone to alleviate certain mood swings and promote breast and heart health, NAD says. The CBBB group recommends Natrol discontinue the use of "Clinically Proven" phrase due to insufficient evidence and modify the "Doctor Recommended" claims to clearly disclose that physicians from Australia and Canada were used in the product's research. The NAD recommendations come after the Center for Science in the Public Interest expressed its concerns with the supplement's ads and labels claims calling for federal intervention (1"The Tan Sheet" Sept. 17, 2007, In Brief)...
You may also be interested in...
CSPI seeks fed block on Promensil ads, labels
The Center for Science in the Public Interest asks FDA and the Federal Trade Commission to halt Natrol's advertising and health claims for its red clover dietary supplement Promensil, indicated for the treatment of hot flashes, night sweats and mood swings. In a Sept. 12 letter to the agencies, CSPI said Natrol's claims that Promensil is "the only supplement proven to reduce menopause symptoms" and that it promotes "heart health" are deceptive and misleading. CSPI says its own analysis of the scientific research to support the efficacy of the supplement showed the data did not support Natrol's claims. The letter requests the Chatsworth, Calif.-based firm reimburse consumers, pay a penalty and run corrective advertising to "set the record straight"...
Can Organovo Leverage Its Solid Phase II Data In MASH?
Cash-limited Organovo has an FXR agonist showing competitive efficacy and tolerability in MASH, but may need a partner to move forward in that disease as it may be prioritizing its IBD program.
Cullinan Changes Tracks, Moving Lymphoma Bispecific Into Autoimmune
The company will discontinue its trial of the CD19-directed bispecific CLN-978 in NHL and develop it in inflammatory diseases, where it could have an edge over CAR-Ts.